Skip to main content

ADAPT –An Efficacy and Safety Study of Infliximab in Pediatric Participants With Inflammatory Bowel Disease

  • Aim: The purpose of this study is to evaluate whether trough serum infliximab concentrations at the time of loss of clinical response will identify pediatric participants with inflammatory bowel disease (IBD) who would benefit (regain clinical response) from dose escalation above the currently approved dose
  • Eligibility: Children with IBD aged 6 to 17 years old who are currently receiving Infliximab (Remicade).
  • Benefits: Stipends for subject and parent. Medication covered by sponsor.
  • More information: